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Abstract: This study was designed to explore the in vitro anticancer effects of the bioactive compounds
isolated from Ricinodendron heudelotii on selected cancer cell lines. The leaves of the plant were
extracted with ethanol and partitioned in sequence with petroleum ether, ethyl acetate, and n-butanol.
The ethyl acetate fraction was phytochemically studied using thin layer chromatography (TLC)
and column chromatography (CC). Structural elucidation of pure compounds obtained from the
ethyl acetate fraction was done using mass spectra, 1H-NMR, and 13C-NMR analysis. The isolated
compounds were subsequently screened using five different cancer cell lines: HL-60, SMMC-7721,
A-549, MCF-7, SW-480, and normal lung epithelial cell line, BEAS-2B, to assess their cytotoxic
effects. Nine compounds were isolated and structurally elucidated as gallic acid, gallic acid ethyl
ester, corilagin, quercetin-3-O-rhamnoside, myricetin-3-O-rhamnoside, 1,4,6-tri-O-galloyl glucose,
3,4,6-tri-O-galloyl glucose, 1,2,6-tri-O-galloyl glucose, and 4,6-di-O-galloyl glucose. Corilagin exhibited
the most cytotoxic activity with an IC50 value of 33.18 µg/mL against MCF-7 cells, which were
comparable to cisplatin with an IC50 value of 27.43 µg/mL. The result suggests that corilagin isolated
from R. heudelotii has the potential to be developed as an effective therapeutic agent against the growth
of breast cancer cells.
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1. Introduction
Cancer is a major cause of death across the globe, affecting all age groups [1]. The World Health
Organization has predicted that cancer cases will increase from 14 million in 2012 to 22 million
in the next four decades [2]. It has caused a great sense of burden both to individual lives and
the society at large [3]. The absolute cure of cancer remains a big challenge despite available
anticancer agents, awareness campaigns, and prevention strategies. Breast and prostate cancer have
the highest incidence in women and men, respectively [4]. It is therefore pertinent to keep exploring
for novel chemotherapeutic agents that can evade drug-resistant cancer cells. Natural or natural
based anti-cancer drugs, such as vincristine, paclitaxel, bleomycin, and others, have been clinically
used over the years [5]. Ricinodendron heudelotii (family: Euphorbiceae) plant parts have been used in
traditional medicine to treat cough, stomach ailments, and pain related to child birth. Decoctions and
infusions are mostly prepared from the leaves and stem bark. Traditional practitioners prescribe it
for women suffering from miscarriages [6]. Phytochemical screening of the leaf extract revealed the
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presence of tannins, terpenoids, glycosides, and alkaloids, and it exhibited antimicrobial effects [7].
Two dinorditerpenoids, 1,2-dihydroheudelotinol and heudelotinone, and three other compounds,
lupeol, E-ferullic acid octacosylate, and 3-methylmethylorsellinate, have been isolated from the stem
bark and roots of R. heudelotii [8]. Seven new tetracyclic triterpenoids ricinodols with potential as
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors has also been reported to be isolated
from R. heudelotii [9]. Yakubu et al. [10] also reported the leaf extract to have regulatory effects on
artemisinin toxicity when co-administered with artemisinin. This study aims to identify the chemical
structure of isolated bioactive compounds in R. heudelotii as well as evaluate the compoundsfor in vitro
cytotoxic activity against human leukemia (HL-60), human hepatocellular carcinoma (SMMC-7721),
human lung adenocarcinoma (A549), human breast cancer cell (MCF-7), and colon adenocarcinoma
(SW480) cell lines.
2. Results
Nine compounds were isolated from the ethyl acetate fraction of R. heudelotii by employing
column chromatography, including Sephadex LH-20 and MCI CHP20P gel.
2.1. Structural Elucidation of Isolated Compounds
Structure elucidation of the isolated compounds was carried out using spectroscopic techniques:
1H- (600 MHz) and 13C-NMR (150 MHz) and DEPT along with 2D-NMR for some compounds
(Figure 1). Compound 1 was obtained as an off-white amorphous powder, showing a molecular
ion peak at m/z 170 [M]− in the negative ESI-MS. The molecular formula, C7H6O5, was deduced
from the combination of 1H-, 13C-NMR and DEPT spectroscopic data. Compound 1 was identified
as gallic acid when the data was compared with those in the literature [11,12]. Compound 2,
an off-white powder, showed a quasi-molecular ion peak at m/z 198 [M]− in the negative ESI-MS.
Combining with the 1H-, 13C-NMR and DEPT spectroscopic data, a molecular formula, C9H10O5,
was deduced. Comparing the data with those in the literature, compound 2 was identified as
gallic acid ethyl ester [13]. Compound 3 was obtained as a yellow amorphous powder, showing
a molecular ion peak at m/z 633 [M]− in the negative ESI-MS. From 1H-, 13C-NMR, and DEPT
spectroscopic data, the molecular formula of C27H22O18 was deduced. Comparing the data with
those in the literature, compound 3 was identified as corilagin [14]. Compound 4 was obtained as
a yellow amorphous powder. It showed a molecular ion peak at m/z 447 [M − H]− in the negative
ESI-MS while the molecular formula of C21H20O11, was deduced from the 1H-, 13C-NMR, and DEPT
spectroscopic data. Likewise, by comparing the data with those in the literature, compound 4 was
quercetin-3-O-rhamnoside [15,16]. Compound 5 was obtained as a pale yellow amorphous powder
showing a quasi-molecular ion peak at m/z 463 [M − H]− in the negative ESI-MS, and the molecular
formula of C21H20O12, was deduced from 1H-, 13C-NMR, and DEPT spectroscopic data. By comparing
the data with those in the literature, compound 5 was identified as myricetin-3-O-rhamnoside [12,17].
Compound 6 was obtained as an off white powder, showing a quasi-molecular ion peak at m/z 635 [M
− H]− in the negative ESI-MS. Combining with the 1H-, 13C-NMR, and DEPT spectroscopic data,
a molecular formula of C27H24O18 was deduced. By comparing the data with those in literature,
compound 6 was identified as 1,4,6-tri-O-galloyl-β-D-glucose [18]. Compound 7 was obtained
as a white amorphous powder. It showed a molecular ion peak at m/z 636 [M − H]− in the
negative ESI-MS. Combining the 1H-, 13C-NMR, and DEPT spectroscopic data, a molecular formula of
C27H24O18 was deduced. The data obtained correlates with those in the literature and compound 7
was identified as 3,4,6-tri-O-galloyl-D-glucose [19]. Compound 8, an off-white amorphous powder
with a molecular ion peak at m/z 635 [M − H]− in the negative ESI-MS. A molecular formula of
C27H24O18, was deduced from the 1H-, 13C-NMR, and DEPT spectroscopic data. Comparing the
data with those in the literature, compound 8 was identified as 1,2,6-tri-O-galloyl-β-D-glucose [20,21].
Compound 9 was obtained as a white amorphous powder showing a molecular ion peat at m/z
483 [M − H]− in the negative ESI-MS. A molecular formula was deduced from the 1H-, 13C-NMR,
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and DEPT spectroscopic data. By comparing the data with those in the literature, compound 9 was
identified as 4,6-di-O-galloyl-D-glucose [22,23].
2.2. Spectroscopic Data of Compounds 1–9
Gallic acid (1): Off-white amorphous powder, C7H6O5, negative ESI-MS m/z: 170 [M]−, 1H-NMR
(600 MHz, acetone-d6): δ 7.10 (2H, s, H-2,6), 13C-NMR (150 MHz, acetone-d6): 121.0 (C-1), 109.0 (C-2,6),
145.9 (C-3,5), 138.3 (C-4), 168.0 (C-7).
Gallic acid ethyl ester (2): Off-white amorphous powder, C9H10O5, negative ESI-MS m/z:
198 [M]−, 1H-NMR (600 MHz, acetone-d6): δH 0.84 (3H, t, J = 7.1 Hz, H-2′), 3.82 (2H, q, J = 7.1 Hz, H-1′)
7.05 (2H, s, H-3,5); 13C-NMR (150 MHz, acetone-d6): δC 120.7 (C-1); 109.4 (C-2,6), 138.0 (C-4), 144.9
(C-3,5), 166.8 (C-7), 60.6 (C-1′), 14.1 (C-2′).
Corilagin (3): Off-white amorphous powder, C27H22O18,negative ESI-MS m/z 633 [M − H]−,
1H-NMR (600, CD3OD): δH 7.05 (2H, s, H-2′,6′),6.69, 6.65 (each 1H, s, HHDP-3”,3
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(1H, dd, J = 1.7, 1.2 Hz, H-4), 4.16 (1H, dd, J = 8.0, 10.9 Hz, H-6b), 3.98 (1H, brd, J = 1.2 Hz, H-2);13C-
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5′′′), 136.3, 136.2 (C-4′′, 4′′′), 116.2, 116.1 (C-1′′, 1′′′), 124.1, 123.8 (C-2′′, 2’’’), 107.3, 106.7 (C-6′′, 6′′′); 
galloyl 𝛿C 165.2 (C=O), 146.2 (C-3′, C-5′), 139.7 (C-4′), 119.4 (C-1′), 109.7 (C-2′, C-6’); glucose 𝛿C92.9 (C-
1), 78.3 (C-3), 76.6 (C-5), 72.4 (C-2), 64.2 (C-6), 62.8 (C-4). 
Quercetin-3-O-rhamnoside (4):Yellow amorphous powder, C21H20O11; negative ESI-MS m/z 447 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 7.33 (1H, d, J = 2.0 Hz, H-2′), 7.31 (1H, dd, J = 2.0, 8.3 Hz, H-
6′), 6.91 (1H, d, J = 8.3 Hz, H-5′), 6.19 (1H, s, H-6), 6.36 (1H, s, H-8), 5.34 (1H, s, H-1′′), 4.22 (1H, brs, H-
2′′), 3.76 (1H, dd, J = 3.2, 9.4 Hz, H-3′′), 3.34 (1H, dd, J = 7.5, 9.4 Hz, H-4′′), 3.41 (1H, m, H-5′′), 0.94 (3H, 
d, J = 6.1 Hz, H-6′′);13C-NMR (150 MHz, CD3OD): δC 18.7 (C-6′′), 71.1 (C-5′′), 70.6 (C3′′), 71.1 (C-2′′), 
71.2 (C-4′′), 94.3 (C-8), 98.7 (C-6), 102.1 (C-1′′), 104.1 (C-10), 115.7 (C-2′), 115.8 (C-5′), 120.8 (C-1′), 122.2 
(C-6′), 134.3 (C-3), 145.4 (C-3′), 148.8 (C-4′), 156.7 (C-2), 157.3 (C-9), 161.4 (C-5), 165.6 (C-7), 177.8 (C-
4). 
Myricetin 3-O-rhamnoside (5):Yellow amorphous powder, C21H20O12, negative ESI-MS m/z: 463 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 6.95 (2H, s, H-2′,6′), 6.36 (1H, d, J = 1.6 Hz, H-6), 6.20 (1H, d, 
J = 1.6 Hz, H-8),5.31 (1H, s, H-1′′),3.80 (1H, dd, J = 3.2, 9.5 Hz, H-2′′), 3.55 (1H, m, H-3′′),, 3.17 (1H, m, 
H-4′′), 3.34 (1H, m, H-5′′), 0.84 (3H, d, J = 6.1Hz, H-6′′). 13C-NMR (150 MHz, CD3OD): δc177.6 (C-4), 
163.8 (C-7), 161.4 (C-5), 157.1 (C-9), 156.6 (C-2), 145.9 (C-5′, 3′), 135.4 (C-4′), 135.2 (C-3), 119.7 (C-1′), 
107.9 (C-2′), 107.9 (C-6′), 104.3 (C-10), 102.4 (C-1′′), 98.8 (C-8), 93.7 (C-6), 71.9 (C-4′′), 71.3 (C-5′′), 70.8 
(C-3′′), 70.3 (C-2′′), 17.8 (C-6′′). 
1,4,6-Tri-O-galloyl-β-D-glucose (6):Off-white amorphous powder, C27H24O18,negative ESI-MS 
m/z 635 [M − H]−;1H-NMR (600 MHz, CD3OD): δH 7.15, 7.10, 7.06 (each 2H, s, galloylH-2′,6′), 5.78 (1H, 
d, J = 8.2 Hz, H-1), 5.22 (1H, t, J = 9.6 Hz, H-4), 4,45 (1H, dd, J = 12.4, 2.0 Hz, H-6a), 4.22 (1H, dd, J = 
12.4, 4.9 Hz, H-6b), 4.06 (1H, ddd, J = 2.0, 4.9, 9.6 Hz, H-5), 3.84 (1H, dd, J = 9.2, 9.6 Hz, H-3), 3.65 (1H, 
dd, J = 8.2, 9.2 Hz, H-2). 
3,4,6-Tri-O-galloyl-D-glucose (7):Off-white amorphous powder, C27H24O18, negative ESI-MS m/z 
635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99,6.94 (each 2H, s,galloylH-2′,6′), 4.42 (1H, m, 
H-6a), 4.26 (1H, m, H-6b), -glucose form: δH 4.76 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5, 7.8 
Hz, H-2), 5.45 (1/3H, t, J = 9.5 Hz, H-3), 5.35 (1/3H, dd, J = 9.5, 9.8 Hz, H-4), 4.07 (1/3H, m, H-5), -
glucose form: δH 5.25 (2/3H, d, J = 3.6 Hz, H-1), 3.81 (2/3H, dd, J = 9.8, 3.6 Hz, H-2), 5.68 (2/3H, t, J = 9.8 
Hz, H-3), 5.36 (2/3H, t, J = 9.8 Hz,H-4), 4.47 (2/3H, m, H-5). 
1,2,6-Tri-O-galloyl-β-D-glucose (8): Off-white amorphous powder, C27H24O18, negative ESI-MS: 
m/z 635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′), 5.92 (1H, 
d, J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4. 56 (1H, dd, J = 2.0, 12.2 Hz, H-6a), 4.47 (1H, dd, 
J = 4.8, 12.2 Hz, H-6b), 3.83 (1H, ddd, J = 2.0, 4.8, 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz, H-3), 3.66 (1H, t, 
J = 9.6 Hz, H-4); 13C-NMR (150MHz, CD3OD): δC 63.1 (C-6), 69.6 (C-4), 72.7 (C-5), 74.4 (C-3), 74.2 (C-
2), 93.2 (C-1), 117.0, 119.1, 119.2 (galloyl C-1′), 109.2, 108.8, 108.8 (galloyl C-2′,6′), 145.3, 145.4, 145.8 
(galloyl C-3′,5′), 138.6, 138.7, 139.1 (galloyl C-4′), 164.1, 164.9, 165.7 (C=O). 
4,6-Di-O-galloyl-β-D-glucose (9):Off-white amorphous powder, C20H20O14, negative ESI-MS: m/z 
483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl H-2′,6′), 5.13 
), 6.36 (1H, d,
J = 2.4 Hz, H-1), 4.95 (1H, ddd, J = 10.9, 8.0, 1.2 Hz, H-6a), 4.80 (1H, brs, H-3), 4.51 (1H, t, J = 9.6 Hz,
H-5), 4.46 (1H, dd, J = 1.7, 1.2 Hz, H-4), 4.16 (1H, dd, J = 8.0, 10.9 Hz, H-6b), 3.98 (1H, brd, J = 1.2 Hz,
H-2); 13C-NMR (150 MHz, CD3OD): HHDP δC 167.1 and 167.6 (C=O), 145.8, 145.1 (C-3”,3
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dd, J = 8.2, 9.2 Hz, H-2). 
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635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99,6.94 (each 2H, s,galloylH-2′,6′), 4.42 (1H, m, 
H-6a), 4.26 (1H, m, H-6b), -glucose form: δH 4.76 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5, 7.8 
Hz, H-2), 5.45 (1/3H, t, J = 9.5 Hz, H-3), 5.35 (1/3H, dd, J = 9.5, 9.8 Hz, H-4), 4.07 (1/3H, m, H-5), -
glucose form: δH 5.25 (2/3H, d, J = 3.6 Hz, H-1), 3.81 (2/3H, dd, J = 9.8, 3.6 Hz, H-2), 5.68 (2/3H, t, J = 9.8 
Hz, H-3), 5.36 (2/3H, t, J = 9.8 Hz,H-4), 4.47 (2/3H, m, H-5). 
1,2,6-Tri-O-galloyl-β-D-glucose (8): Off-white amorphous powder, C27H24O18, negative ESI-MS: 
m/z 635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′), 5.92 (1H, 
d, J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4. 56 (1H, dd, J = 2.0, 12.2 Hz, H-6a), 4.47 (1H, dd, 
J = 4.8, 12.2 Hz, H-6b), 3.83 (1H, ddd, J = 2.0, 4.8, 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz, H-3), 3.66 (1H, t, 
J = 9.6 Hz, H-4); 13C-NMR (150MHz, CD3OD): δC 63.1 (C-6), 69.6 (C-4), 72.7 (C-5), 74.4 (C-3), 74.2 (C-
2), 93.2 (C-1), 117.0, 119.1, 119.2 (galloyl C-1′), 109.2, 108.8, 108.8 (galloyl C-2′,6′), 145.3, 145.4, 145.8 
(galloyl C-3′,5′), 138.6, 138.7, 139.1 (galloyl C-4′), 164.1, 164.9, 165.7 (C=O). 
4,6-Di-O-galloyl-β-D-glucose (9):Off-white amorphous powder, C20H20O14, negative ESI-MS: m/z 
483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl H-2′,6′), 5.13 
), 144.9,
144.3 (C-5”,5
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2.2.Spectroscopic Data of Compounds 1–9 
Gallic acid (1): Off-white amorphous powder, C7H6O5, negative ESI-MS m/z: 170 [M]−, 1H-NMR 
(600MHz, acetone-d6): δ 7.10 (2H, s, H-2,6), 13C-NMR (150MHz, acetone-d ): 121.0 (C-1), 109.0 (C-2,6), 
145.9 (C-3,5), 138.3 (C-4), 168.0 (C-7). 
Gallic acid ethyl ester (2):Off-white amorphous powder, C9H10O5, negative ESI-MS m/z: 198 [M]−, 
1H-NMR (600MHz, acetone-d6): δH 0.84 (3H, t, J = 7.1 Hz, H-2′), 3.82 (2H, q, J = 7.1 Hz, H-1′) 7.05 (2H, 
s, H-3,5); 13C-NMR (150 MHz, acetone-d6): δC  120.7(C-1); 109.4 (C-2,6), 138.0 (C-4), 144.9 (C-3, 5), 166.8 
(C-7), 60.6 (C-1′), 14.1 (C-2′). 
Corilagin (3): Off-white amorphous powder,C27H22O18,negative ESI-MS m/z 633 [M − H]−, 1H-
NMR (600, CD3OD): δH 7.05 (2H, s, H-2′,6′),6.69, 6.65 (each 1H, s, HHDP-3′′,3′′′), 6.36 (1H, d, J = 2.4 Hz, 
H-1), 4.95 (1H, ddd, J = 10.9, 8.0, 1.2 Hz, H-6a), 4.80 (1H, brs, H-3), 4.51 (1H, t, J = 9.6 Hz, H-5), 4.46 
(1H, dd, J = 1.7, 1.2 Hz, H-4), 4.16 (1H, dd, J = 8.0, 10.9 Hz, H-6b), 3.98 (1H, brd, J = 1.2 Hz, H-2);13C-
NMR (150MHz, CD3OD): HHDP 𝛿C 167.1 and 167.6 (C=O), 145.8, 145.1 (C-3′′, 3′′′), 144.9, 144.3 (C-5′′, 
5′′′), 136.3, 136.2 (C-4′′, 4′′′), 116.2, 116.1 (C-1′′, 1′′′), 124.1, 123.8 (C-2′′, 2’’’), 107.3, 106.7 (C-6′′, 6′′′); 
galloyl 𝛿C 165.2 (C=O), 146.2 (C-3′, C-5′), 139.7 (C-4′), 119.4 (C-1′), 109.7 (C-2′, C-6’); glucose 𝛿C92.9 (C-
1), 78.3 (C-3), 76.6 (C-5), 72.4 (C-2), 64.2 (C-6), 62.8 (C-4). 
Quercetin-3-O-rhamnoside (4):Yellow amorphous powder, C21H20O11; negative ESI-MS m/z 447 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 7.33 (1H, d, J = 2.0 Hz, H-2′), 7.31 (1H, dd, J = 2.0, 8.3 Hz, H-
6′), 6.91 (1H, d, J = 8.3 Hz, H-5′), 6.19 (1H, s, H-6), 6.36 (1H, s, H-8), 5.34 (1H, s, H-1′′), 4.22 (1H, brs, H-
2′′), 3.76 (1H, dd, J = 3.2, 9.4 Hz, H-3′′), 3.34 (1H, dd, J = 7.5, 9.4 Hz, H-4′′), 3.41 (1H, m, H-5′′), 0.94 (3H, 
d, J = 6.1 Hz, H-6′′);13C-NMR (150 MHz, CD3OD): δC 18.7 (C-6′′), 71.1 (C-5′′), 70.6 (C3′′), 71.1 (C-2′′), 
71.2 (C-4′′), 94.3 (C-8), 98.7 (C-6), 102.1 (C-1′′), 104.1 (C-10), 115.7 (C-2′), 115.8 (C-5′), 120.8 (C-1′), 122.2 
(C-6′), 134.3 (C-3), 145.4 (C-3′), 148.8 (C-4′), 156.7 (C-2), 157.3 (C-9), 161.4 (C-5), 165.6 (C-7), 177.8 (C-
4). 
Myricetin 3-O-rhamnoside (5):Yellow amorphous powder, C21H20O12, negative ESI-MS m/z: 463 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 6.95 (2H, s, H-2′,6′), 6.36 (1H, d, J = 1.6 Hz, H-6), 6.20 (1H, d, 
J = 1.6 Hz, H-8),5.31 (1H, s, H-1′′),3.80 (1H, dd, J = 3.2, 9.5 Hz, H-2′′), 3.55 (1H, m, H-3′′),, 3.17 (1H, m, 
H-4′′), 3.34 (1H, m, H-5′′), 0.84 (3H, d, J = 6.1Hz, H-6′′). 13C-NMR (150 MHz, CD3OD): δc177.6 (C-4), 
163.8 (C-7), 161.4 (C-5), 157.1 (C-9), 156.6 (C-2), 145.9 (C-5′, 3′), 135.4 (C-4′), 135.2 (C-3), 119.7 (C-1′), 
107.9 (C-2′), 107.9 (C-6′), 104.3 (C-10), 102.4 (C-1′′), 98.8 (C-8), 93.7 (C-6), 71.9 (C-4′′), 71.3 (C-5′′), 70.8 
(C-3′′), 70.3 (C-2′′), 17.8 (C-6′′). 
1,4,6-Tri-O-galloyl-β-D-glucose (6):Off-white amorphous powder, C27H24O18,negative ESI-MS 
m/z 635 [M − H]−;1H-NMR (600 MHz, CD3OD): δH 7.15, 7.10, 7.06 (each 2H, s, galloylH-2′,6′), 5.78 (1H, 
d, J = 8.2 Hz, H-1), 5.22 (1H, t, J = 9.6 Hz, H-4), 4,45 (1H, dd, J = 12.4, 2.0 Hz, H-6a), 4.22 (1H, dd, J = 
12.4, 4.9 Hz, H-6b), 4.06 (1H, ddd, J = 2.0, 4.9, 9.6 Hz, H-5), 3.84 (1H, dd, J = 9.2, 9.6 Hz, H-3), 3.65 (1H, 
dd, J = 8.2, 9.2 Hz, H-2). 
3,4,6-Tri-O-galloyl-D-glucose (7):Off-white amorphous powder, C27H24O18, negative ESI-MS m/z 
635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99,6.94 (each 2H, s,galloylH-2′,6′), 4.42 (1H, m, 
H-6a), 4.26 (1H, m, H-6b), -glucose form: δH 4.76 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5, 7.8 
Hz, H-2), 5.45 (1/3H, t, J = 9.5 Hz, H-3), 5.35 (1/3H, dd, J = 9.5, 9.8 Hz, H-4), 4.07 (1/3H, m, H-5), -
glucose form: δH 5.25 (2/3H, d, J = 3.6 Hz, H-1), 3.81 (2/3H, dd, J = 9.8, 3.6 Hz, H-2), 5.68 (2/3H, t, J = 9.8 
Hz, H-3), 5.36 (2/3H, t, J = 9.8 Hz,H-4), 4.47 (2/3H, m, H-5). 
1,2,6-Tri-O-galloyl-β-D-glucose (8): Off-white amorphous powder, C27H24O18, negative ESI-MS: 
m/z 635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′), 5.92 (1H, 
d, J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4. 56 (1H, dd, J = 2.0, 12.2 Hz, H-6a), 4.47 (1H, dd, 
J = 4.8, 12.2 Hz, H-6b), 3.83 (1H, ddd, J = 2.0, 4.8, 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz, H-3), 3.66 (1H, t, 
J = 9.6 Hz, H-4); 13C-NMR (150MHz, CD3OD): δC 63.1 (C-6), 69.6 (C-4), 72.7 (C-5), 74.4 (C-3), 74.2 (C-
2), 93.2 (C-1), 117.0, 119.1, 119.2 (galloyl C-1′), 109.2, 108.8, 108.8 (galloyl C-2′,6′), 145.3, 145.4, 145.8 
(galloyl C-3′,5′), 138.6, 138.7, 139.1 (galloyl C-4′), 164.1, 164.9, 165.7 (C=O). 
4,6-Di-O-galloyl-β-D-glucose (9):Off-white amorphous powder, C20H20O14, negative ESI-MS: m/z 
483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl H-2′,6′), 5.13 
), 1 .3, 136.2 (C-4”,4
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2.2.Spectroscopic Data of Compounds 1–9 
Gallic acid (1): Off-white amorphous powder, C7H6O5, negative ESI-MS m/z: 170 [M]−, 1H-NMR 
(6 0MHz acetone-d6): δ 7.10 (2H, s, H-2,6), 13C-NMR (150MHz, acetone-d6 : 21.0 (C-1), 109.0 (C-2,6), 
45 9 3,5), 138.3 (C-4), 168.0 (C-7). 
Gallic acid ethyl ester (2):Off-white amorphous powder, C9H10O5, negative ESI-MS m/z: 198 [M]−, 
1H-NMR (600M z, acetone-d6): δH 0.84 (3H, t, J = 7.1 Hz, H-2′), 3.82 (2 , q, J = 7.1 Hz, H-1′) 7.05 (2H, 
s, H-3,5); 13C NMR (150 MHz, acetone-d6): δC  120.7( -1); 109.4 ( -2,6 38 0 (C-4), 144.9 (C-3, 5), 166.8 
(C-7), 60.6 (C-1′), 14.1 (C-2′). 
Corilagin (3): Off-white amorphous powder,C27H22O18,negative ESI-MS m/z 633 [M − H]−, 1 -
NMR (600, CD3OD): δH 7.05 (2H, s, H-2′,6′),6.69, 6.65 (each 1H, s, HHDP-3′′,3′′′), 6.36 (1H, d, J = 2.4 Hz, 
H-1), 4.95 (1H, ddd, J = 10.9, 8.0, 1.2 z, H-6a), 4.80 (1H, brs, H-3), 4.51 (1H, t, J = 9.6 Hz, H-5), 4.46 
(1H, dd, J = 1.7, 1.2 Hz, H-4), 4.16 (1H, dd, J = 8.0 10.9 Hz, H-6b) 3.98 (1H, brd, J = 1.2 Hz, H-2);13C-
NMR (150MHz, CD3OD): HHDP 𝛿C 167.  and 167.6 (C=O), 145.8, 145.  (C-3′′, 3′′′), 144.9, 144.3 (C-5′′, 
5′′′), 36.3, 36.2 (C-4′′, 4′′′), 116.2, 116.1 (C-1′′, 1′′′), 124.1, 123.8 (C-2′′, 2’’’), 107.3, 106.7 (C-6′′, 6′′′); 
galloyl 𝛿C 165.2 (C=O), 1 6.2 (C-3′, C-5′), 139.7 (C-4′), 119.4 (C-1′), 10 .7 (C-2′, -6’); glucose 𝛿C92.9 ( -
1), 78.3 (C-3), 76.6 (C-5), 72.4 (C-2), 64.2 (C-6), 62.8 (C-4). 
Quercetin-3-O-rhamn side (4):Yellow amorphous powder, C21H20O11; negative ESI-MS m/z 447 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 7.33 (1H, d, J = 2.0 Hz, H-2′), 7.31 (1H, dd, J = 2.0, 8.3 z, H-
6′), 6.91 (1H, d, J = 8.3 Hz, H-5′), 6.19 (1H, s, H-6), 6.36 (1H, s, H-8), 5.34 (1 , s, H-1′′), 4.22 (1H, brs, H-
2′′), 3.76 (1H, dd, J = 3.2, 9.4 Hz, H-3′′), 3.34 (1H, dd, J = 7.5, 9.4 Hz, H-4′′), 3.41 (1H, m, H-5′′), 0.94 (3H, 
d, J = 6.1 Hz, H-6′′);13C-NMR (150 MHz, CD3OD): δC 18.7 (C-6′′), 7 .1 (C-5′′), 70.6 (C3′′), 71.1 (C-2′′), 
1.2 (C-4′′), 94.3 (C-8), 98.7 (C-6), 102.1 ( -1′ 04 1 10), 115.7 (C-2′), 115.8 (C-5′), 120.8 (C-1′), 122.2 
(C-6′), 134.3 (C-3), 45.4 ( -3′), 148.8 (C-4′), 156.7 (C-2), 1 7.3 (C-9), 161.4 (C-5), 165.6 (C-7), 177.8 (C-
4). 
Myricetin 3-O-rhamnoside (5):Yellow amorphous powder, C21H20O12, negative ESI-MS m/z: 463 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 6.95 (2H, s, H-2′ 6′), .3  (1H, d, J = 1.6 z, H-6), 6.20 (1 , d, 
J = 1.6 Hz, H-8),5.31 (1H, s, H-1′′),3.80 (1H dd, J = 3.2, 9.5 Hz, H-2′′), 3.55 (1H, m, -3′′),, 3.17 (1H, m, 
H-4′′), .34 (1H, m, -5′′), 0.84 (3H, d, J = 6.1Hz, H-6′′). 13C-NMR (150 MHz, CD3OD): δc177.6 (C-4), 
163.8 (C-7), 1 1.4 (C-5), 1 7.1 (C-9), 156.6 (C-2), 145.9 (C-5′, ′), 135.4 (C-4′), 135.2 (C-3), 119.7 (C-1′), 
7.9 ( -2′), 7.9 ( -6′), 104.3 ( -10), 102.4 (C-1′′), 98.8 (C-8), 93.7 (C-6), 71.9 (C-4′′), 71.3 (C-5′′), 70.8 
(C-3′′), 70.3 (C-2′′), 17.8 (C-6′′). 
1,4,6-Tri-O-galloyl-β-D-glucose (6):Off-white amorphous powder, C27H24O18,negative ESI-MS 
m/z 635 [M − H]−;1H-NMR (600 MHz, CD3OD): δH 7.15, 7.10, 7.0  (each 2H, s, galloylH-2′,6′), 5.78 (1H, 
d, J = 8.2 Hz, H-1), 5.22 (1H, t, J = 9.6 Hz, H-4), 4,45 (1H, dd, J = 2.4, 2.0 Hz, H-6a), 4.22 (1H, dd, J = 
12.4, 4.9 Hz, H-6b), 4.06 (1H, ddd, J = 2.0, 4.9, 9.6 Hz, H-5), 3.84 (1H, dd, J = 9.2, 9.6 Hz, H-3), 3.65 (1H, 
dd, J = 8.2, 9.2 Hz, H-2). 
3,4,6-Tri-O galloyl-D-gluc se (7):Off-white amorphous powder, C27H24O18, negative ESI-MS m/z 
635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99,6.94 (each 2 , s,galloylH-2′,6′), 4.42 (1H, m, 
H-6a), 4.26 (1H, m, H-6b), -glucose form: δH 4.76 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5, 7.8 
Hz, H-2), 5.45 (1/ H, t, J = 9.5 Hz, H-3), 5.35 (1/3H dd, J = 9.5 9.8 z, H-4), 4.07 (1/3H, m, H-5), -
glucose form: δ  5.25 (2/3H, d, J = 3.6 Hz, H-1), 3.81 (2/3H, dd, J = 9.8, 3.6 z, H-2), 5.68 (2/3H, t, J = 9.8 
Hz, -3), 5.36 (2/3H, t, J = 9.8 Hz,H-4), 4.47 (2/3H, m, H-5). 
1,2,6-Tri-O-galloyl-β-D-glucose (8): Off-white amorphous powder, C27H24O18, negative ESI-MS: 
m/z 635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′), 5.92 (1H, 
d J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4. 56 (1H, dd, J = 2.0, 12.2 Hz, H-6a), 4.47 (1H, dd, 
J = 4.8 12.2 Hz, H-6b), 3.83 (1H, ddd, J = 2.0, 4.8, 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz, H-3), 3.66 (1H, t, 
J = 9.6 Hz, H-4); 13C-NMR ( 50MHz, CD3OD): δC 63.1 (C-6), 69.6 (C-4), 72.7 (C-5), 74.4 (C-3), 74.2 (C-
2), 93.  (C-1), 117.0, 1 9.1, 1 9.2 (galloyl C-1′), 109. , 108.8, 108.8 (galloyl C-2′,6′), 145.3, 145.4, 145.8 
(galloyl C-3′,5′), 138.6, 138.7, 139.1 (galloyl -4′ , 164.1, 164.9, 165.7 (C=O). 
4,6-Di- -galloyl-β-D-gluc se (9):Off-white amorphous powder, C20H20O14, negative ESI-MS: m/z 
483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl H-2′,6′), 5.13 
), 11 .2, 116.1 (C-1”,1
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2.2.Spectroscopic Data of Compounds 1–9 
Gallic acid (1): Off-white amorphous powder, C7 6O5, negative ESI-MS m/z: 170 [M]−, 1H-NMR 
(6 0MHz acetone-d6): δ 7.10 (2H, s, H-2,6), 13C-NMR (150MHz, acetone-d6 : 121.0 (C-1), 109.0 (C-2,6), 
45 9 3,5), 138.3 (C-4), 168.0 (C-7). 
Gallic acid ethyl ester (2):Off-white amorphous powder, C9H10O5, negative ESI-MS m/z: 198 [M]−, 
1H-NMR (600M z, acetone-d6): δH 0.84 (3H, t, J = 7.1 Hz, H-2′), 3.82 (2H, q, J = 7.1 Hz, H-1′) 7.05 (2H, 
s, H-3,5); 13C NMR ( 50 MHz, acetone-d6): δC  120.7( -1); 109.4 ( -2,6 38 0 (C-4), 144.9 (C-3, 5), 166.8 
(C-7), 60.6 (C-1′), 14.1 (C-2′). 
Corilagin (3): Off white amorphous powder,C27H22O18,negative ESI-MS m/z 633 [M − H]−, 1H-
NMR (600, CD3O ): δH 7.05 (2H, s, -2′ 6′),6.69, 6.65 (each 1H, s, HHDP-3′′,3′′′), 6.36 (1H, d, J = 2.4 Hz, 
H- ), 4.95 (1H, ddd, J = 10.9, 8.0, 1.2 z, H-6a), 4.80 (1H, brs, -3), 4.51 (1H, t, J = 9.6 Hz, H-5), 4.46 
(1H, dd, J = 1.7, 1.2 Hz, H-4), 4.16 (1 , dd, J = 8.0 10.9 z, H-6b) 3.98 (1H, brd, J = .2 Hz, H-2);13C-
NMR (150MHz, CD3OD): HHDP 𝛿C 167.  and 167.6 (C=O), 145.8, 145.1 (C-3′′, 3′′′), 144.9, 144.3 (C-5′′, 
5′′′), 36.3, 36.2 (C-4′′, 4′′′), 116.2, 116.1 (C-1′′, 1′′′), 124.1, 123.8 (C-2′′, 2’’’), 107.3, 106.7 (C-6′′, 6′′′); 
galloyl 𝛿  165.2 (C=O), 1 6.2 (C-3′, C-5′), 139.7 (C-4′), 119.4 (C-1′), 10 .7 (C-2′, C-6’); glucose 𝛿C92.9 (C-
1), 78.3 (C-3), 76.6 (C-5), 72.4 (C-2), 64.2 (C-6), 62.8 (C-4). 
Quercetin-3-O-rhamn side (4):Yellow amorphous powder, C21H20O11; negative ESI-MS m/z 447 
[M − H]−, 1H-NMR (600 M z, CD3OD): δ 7.33 (1 , d, J = 2.0 Hz, H-2′), 7.31 (1H, dd, J = 2.0, 8.3 Hz, -
6′), 6.91 (1 , d, J = 8.3 z, H-5′), 6.19 (1H, s, H-6), 6.36 (1H, s, H-8), 5.34 (1 , s, H-1′′), 4.22 (1H, brs, H-
2′′), 3 76 (1H, dd, J = 3.2, 9.4 Hz, H-3′′), 3.34 (1H, dd, J = 7.5, 9.4 Hz, H-4′′), 3.41 (1H, m, H-5′′), 0.94 (3H, 
d, J = 6.1 Hz, H-6′′);13C-NMR (150 MHz, CD3OD): δC 18.7 (C-6′′), 7 .1 (C-5′′), 70.6 (C3′′), 71.1 (C-2′′), 
1.2 (C-4′′), 94.3 (C-8), 98.7 (C-6), 02.1 ( - ′ 04 1 10), 115.7 (C-2′), 115.8 (C-5′), 120.8 (C-1′), 122.2 
(C-6′), 134.3 (C-3), 45.4 ( -3′), 148.8 (C-4′), 156.7 (C-2), 1 7.3 (C-9), 161.4 (C-5), 165.6 (C-7), 77.8 (C-
4). 
Myric tin 3-O-rhamnoside (5):Yellow amorphous powder, C21H20O12, negative ESI-MS m/z: 463 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 6.95 (2H s, H-2′ 6′), .3  (1H, d, J = 1.6 Hz, -6), 6.20 (1H, d, 
J = 1.6 z, -8),5. 1 (1H, s H-1′′), .80 (1H dd, J = 3.2, 9.5 Hz, H-2′′), 3.55 (1H, m, H-3′′),, 3.17 (1H, m, 
H-4′′), .34 (1H, m, -5′′), 0.84 (3H, d, J = .1Hz, H-6′′). 13C-NMR (150 MHz, CD3OD): δc177.6 (C-4), 
163.8 (C-7), 1 1.4 (C-5), 1 7.1 (C-9), 156.6 (C-2), 145.9 (C-5′, ′), 135.4 (C-4′), 135.2 (C-3), 119.7 (C-1′), 
7.9 (C-2′), 7.9 ( -6′), 104.3 ( -10), 102.4 (C-1′′), 98.8 (C-8), 93.7 (C-6), 71.9 (C-4′′), 71.3 (C-5′′), 70.8 
(C-3′′), 70.3 (C-2′′), 17.8 (C-6′′). 
1,4,6-Tri-O-galloyl-β-D-glucose (6):Off-white amorphous powder, C27 24O18,negative ESI-MS 
m/z 635 [M − H]−;1H-NMR (600 M z, CD3OD): δH 7.15, 7.10, 7.0  (each 2H, s, galloylH-2′,6′), 5.78 (1H, 
d, J = 8.2 Hz, H-1), 5.22 (1H, t, J = 9.6 Hz, H-4), 4,45 (1H, dd, J = 2.4, 2.0 Hz, H-6a), 4.22 (1 , dd, J = 
12.4, 4.9 Hz, H-6b), 4.06 (1H, ddd, J = 2.0 4 9, 9.6 Hz, H-5), 3.84 (1H, dd, J = 9.2, 9.6 Hz, H-3), 3.65 (1H, 
dd, J = 8.2, 9.2 Hz, H-2). 
3,4,6-Tri-O galloyl-D-gluc se (7):Off-white amorphous powder, C27H24O18, negative ESI-MS m/z 
635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99,6.94 (each 2H, s,galloylH-2′,6′), 4.42 (1H, m, 
H-6a), 4.26 (1H, m, -6b), -glucose form: δH 4. 6 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5, 7.8 
Hz, H-2), 5.45 (1/ H, t, J = 9 5 Hz, -3), 5.35 (1/3H dd, J = 9.5 9.8 z, H-4), 4.07 (1/3H, m, H-5), -
glucose form: δ  5.25 (2/3 , d, J = 3.6 Hz, H-1), 3.81 (2/3H, dd, J = 9.8, 3.6 z, -2), 5.68 (2/3 , t, J = 9.8 
Hz, -3), 5.36 (2/3H, t, J = 9.8 Hz,H-4), 4.47 (2/3H, m, H-5). 
1,2,6-Tri-O-galloyl-β-D-glucose (8): Off-white amorphous powder, C27H24O18, negative ESI-MS: 
m/z 635 [M − H]−, 1H-NMR (600 M z, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′), 5.92 (1H, 
d J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4. 56 (1 , dd, J = 2.0, 12.2 Hz, H-6a), 4.47 (1H, dd, 
J = 4.8 12.2 Hz, H-6b) 3.83 (1 , ddd, J = 2.0, 4.8 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz, H-3), 3.66 (1H, t, 
J = 9.6 Hz, H-4); 13C-NMR ( 0MHz, D3OD): δ  63.1 (C-6), 69.6 (C-4), 72.7 (C-5), 74.4 (C-3), 74.2 (C-
2) 93.  (C-1), 117.0, 1 9.1, 1 9.2 (galloyl C-1′), 109. , 108.8, 108.8 (galloyl C-2′,6′), 145.3, 145.4, 145.8 
(galloyl C-3′, ′), 138.6, 138.7, 139.1 (galloyl -4′ , 164.1, 164.9, 165.7 (C=O). 
4,6-Di- -galloyl-β-D-gluc se (9):Off-white amorphous powder, C20H20O14, negative ESI-MS: m/z 
483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl H-2′,6′), 5.13 
), 124. , 123.8 (C-2”,2
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2.2.Spectroscopic Data of Compounds 1–9 
Gallic acid (1): Off-white amorph us powder, C7 6O5, negative ESI-MS m/z: 170 [M]−, 1H-NMR 
(6 0MHz acetone-d6): δ 7.10 (2H, s, H-2,6), 13C-NMR (150MHz, acetone-d6 : 121.0 (C-1), 109.0 (C-2,6), 
45 9 3,5), 138.3 (C-4), 168.0 (C-7). 
Gallic acid ethyl ester (2):Off-white amorphous powder, C9H10O5, negative ESI-MS m/z: 198 [M]−, 
1H-NMR (600M z, acetone-d6): δH 0.84 (3H, t, J = 7.1 Hz, H-2′), 3.82 (2H, q, J = 7.1 Hz, H-1′) 7.05 (2H, 
s, H-3,5); 13C NMR ( 50 MHz, acetone-d6): δC  120.7( -1); 109.4 ( -2,6 38 0 (C-4), 144.9 (C-3, 5), 166.8 
(C-7), 60.6 (C-1′), 14.1 (C-2′). 
Corilagin (3): Off white amorphous powder,C27H22O18,negative ESI-MS m/z 633 [M − H]−, 1H-
NMR (600, CD3O ): δH 7.05 (2 , s, -2′ 6′),6.69, 6.65 (each 1 , s, HHDP-3′′,3′′′), 6.36 (1H, d, J = 2.4 Hz, 
H- ), 4.95 (1H, ddd, J = 10.9, 8.0, 1.2 z, -6a), 4.80 (1H, brs, H-3), 4.51 (1H, t, J = 9.6 Hz, -5), 4.46 
(1H, dd, J = 1.7, 1.2 Hz, H-4), 4.16 (1 , dd, J = 8.0 10.9 Hz, H-6b) 3.98 (1H, brd, J = .2 Hz, H-2);13C-
NMR ( 50MHz, CD3OD): HHDP 𝛿C 167.  and 167.6 (C=O), 145.8, 145.1 (C-3′′, 3′′′), 144.9, 144.3 (C-5′′, 
5′′′), 36.3, 36.2 (C-4′′, 4′′′), 116.2, 116.1 (C-1′′, 1′′′), 124.1, 123.8 (C-2′′, 2’’’), 107.3, 106.7 (C-6′′, 6′′′); 
galloyl 𝛿  165.2 (C=O), 1 6.2 (C-3′, C-5′), 139.7 (C-4′), 119.4 (C-1′), 10 .7 (C-2′, C-6’); glucose 𝛿C92.9 (C-
1), 78.3 (C-3), 76.6 (C-5), 72.4 (C-2), 64.2 (C-6), 62.8 (C-4). 
Quercetin-3-O-rhamn side (4):Yellow amorphous powder, C21H20O11; negative ESI-MS m/z 447 
[M − H]−, 1H-NMR (600 M z, CD3OD): δ 7.33 (1 , d, J = 2.0 Hz, H-2′), 7.31 (1H, dd, J = 2.0, 8.3 Hz, H-
6′), 6.91 (1 , d, J = 8.3 z, H-5′), 6.19 (1H, s, H-6), 6.36 (1H, s, H-8), 5.34 (1 , s, H-1′′), 4.22 (1H, brs, H-
2′′), 3 76 (1H, dd, J = 3.2, 9.4 z, -3′′), 3.34 (1H, dd, J = 7.5, 9.4 Hz, H-4′′), 3.41 (1H, m, H-5′′), 0.94 (3H, 
d, J = 6.1 Hz, H-6′′);13C-NMR (150 MHz, CD3OD): δC 18.7 (C-6′′), 7 .1 (C-5′′), 70.6 (C3′′), 71.1 (C-2′′), 
1.2 (C-4′′), 94.3 (C-8), 98.7 (C-6), 02.1 ( - ′ 04 1 10), 115.7 (C-2′), 115.8 (C-5′), 120.8 (C-1′), 122.2 
(C-6′), 134.3 (C-3), 45.4 ( -3′), 148.8 (C-4′), 156.7 (C-2), 1 7.3 (C-9), 161.4 (C-5), 165.6 (C-7), 177.8 (C-
4). 
Myric tin 3-O-rhamnoside (5):Yellow amorphous powder, C21H20O12, negative ESI-MS m/z: 463 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 6.95 (2H s, H-2′ 6′), .3  (1H, d, J = 1.6 z, H-6), 6.20 (1H, d, 
J = 1.6 z, -8),5. 1 (1H s H-1′′), .80 (1H dd, J = 3.2, 9.5 Hz, H-2′′), 3.55 (1H, m, H-3′′),, 3.17 (1H, m, 
H-4′′), .34 (1H, m, -5′′), 0.84 (3H, d, J = .1Hz, H-6′′). 13C-NMR (150 MHz, CD3OD): δc177.6 (C-4), 
163.8 (C-7), 1 1.4 (C-5), 1 7.1 (C-9), 156.6 (C-2), 145.9 (C-5′, ′), 135.4 (C-4′), 135.2 (C-3), 119.7 (C-1′), 
7.9 (C-2′), 7.9 ( -6′), 104.3 ( -10), 102.4 (C-1′′), 98.8 (C-8), 93.7 (C-6), 71.9 (C-4′′), 71.3 (C-5′′), 70.8 
(C-3′′), 70.3 (C-2′′), 17.8 (C-6′′). 
1,4,6-Tri-O-galloyl-β-D-glucose (6):Off-white amorphous powder, C27H24O18,negative ESI-MS 
m/z 635 [M − H]−;1H-NMR (600 M z, CD3OD): δH 7.15, 7.10, 7.0  (each 2 , s, galloylH-2′,6′), 5.78 (1H, 
d, J = 8.2 Hz, H-1), 5.22 (1 , t, J = 9.6 Hz, H-4), 4,45 (1H, dd, J = 2.4, 2.0 Hz, H-6a), 4.22 (1H, dd, J = 
12.4, 4.9 Hz, H-6b), 4.06 (1H, ddd, J = 2.0 4 9, 9.6 Hz, H-5), 3.84 (1H, dd, J = 9.2, 9.6 Hz, H-3), 3.65 (1H, 
dd, J = 8.2, 9.2 Hz, H-2). 
3,4,6-Tri-O galloyl-D-gluc se (7):Off-white amorphous powder, C27H24O18, negative ESI-MS m/z 
635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99,6.94 (each 2H, s,galloylH-2′,6′), 4.42 (1H, m, 
H- a), 4.26 (1H, m, -6b), -glucose form: δH 4. 6 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5, 7.8 
Hz, H-2), 5.45 (1/ H, t, J = 9 5 Hz, -3), 5.35 (1/3H dd, J = 9.5 9.8 z, H-4), 4.07 (1/3H, m, H-5), -
glucose form: δ 5.25 (2/3 , d, J = 3.6 Hz, H-1), 3.81 (2/3H, dd, J = 9.8, 3.6 Hz, H-2), 5.68 (2/3H, t, J = 9.8 
Hz, -3), 5.36 (2/3H, t, J = 9.8 Hz,H-4), 4.47 (2/3H, m, H-5). 
2,6-Tri-O-galloyl-β-D-glucose (8): Off-white amorphous powder, C27H24O18, negative ESI-MS: 
m/z 635 [M − H]−, 1H-NMR (600 M z, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′), 5.92 (1 , 
d J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4. 56 (1H, dd, J = 2.0, 12.2 Hz, H-6a), 4.47 (1H, dd, 
J = 4.8 12.2 Hz, H-6b) 3.83 (1 , ddd, J = 2.0, 4.8 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz, H-3), 3.66 (1H, t, 
J = 9.6 Hz, H-4); 13C-NMR ( 0MHz, D3OD): δ  63.1 (C-6), 69.6 (C-4), 72.7 (C-5), 74.4 (C-3), 74.2 (C-
2) 93.  (C-1), 117.0, 1 9.1, 1 9.2 (galloyl C-1′), 109. , 108.8, 108.8 (galloyl C-2′,6′), 145.3, 145.4, 145.8 
(galloyl C-3′, ′), 138.6, 138.7, 139.1 (galloyl -4′ , 164.1, 164.9, 165.7 (C=O). 
4,6-Di- -galloyl-β-D-gluc se (9):Off-white amorphous powder, C20H20O14, negative ESI-MS: m/z 
483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl H-2′,6′), 5.13 
), 107.3, 106.7 (C-6”,6
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2.2.Spectroscopic Data of Compounds 1–9 
Gallic acid (1): Off-white amorphous powder, C7H6O5, negative ESI-MS m/z: 170 [M]−, 1H-NMR 
(6 0MHz acetone-d6): δ 7.10 (2H, s, H-2,6), 13C-NMR (150MHz, acetone-d6 : 121.0 (C-1), 109.0 (C-2,6), 
45 9 3,5), 138.3 (C-4), 168.0 (C-7). 
Gallic acid ethyl ester (2):Off-white amorphous powder, C9H10O5, negative ESI-MS m/z: 198 [M]−, 
1H-NMR (600M z, acetone-d6): δH 0.84 (3H, t, J = 7.1 Hz, H-2′), 3.82 (2H, q, J = 7.1 Hz, H-1′) 7.05 (2H, 
s, H-3,5); 13C NMR ( 50 MHz, acetone-d6): δC  120.7( -1); 109.4 ( -2,6 38 0 (C-4), 44.9 (C-3, 5), 166.8 
(C-7), 60.6 (C-1′), 14.1 (C-2′). 
Corilagin (3): Off white amorphous powder,C27H22O18,negative ESI-MS m/z 633 [M − H]−, 1H-
NMR (600, CD3O ): δH 7.05 (2 , s, -2′ 6′),6.69, 6.65 (each 1H, s, HHDP-3′′,3′′′), 6.36 (1H, d, J = 2.4 Hz, 
H- ), 4.95 (1 , ddd, J = 10.9, 8.0, 1.2 z, H-6a), 4.80 (1H, brs, H-3), 4.51 (1H, t, J = 9.6 Hz, H-5), 4.46 
(1H, dd, J = 1.7, 1.2 Hz, H-4), 4.16 (1 , dd, J = 8.0 10.9 Hz, H-6b) 3.98 (1H, brd, J = 1.2 Hz, H-2);13C-
NMR ( 50MHz, CD3OD): HHDP 𝛿C 167.  and 167.6 (C=O), 145.8, 145.1 (C-3′′, 3′′′), 144.9, 144.3 (C-5′′, 
5′′′), 36.3, 36.2 (C-4′′, 4′′′), 116.2, 116.1 (C-1′′, 1′′′), 124.1, 123.8 (C-2′′, 2’’’), 107.3, 106.7 (C-6′′, 6′′′); 
galloyl 𝛿  165.2 (C=O), 1 6.2 (C-3′, C-5′), 139.7 (C-4′), 119.4 (C-1′), 10 .7 (C-2′, C-6’); glucose 𝛿C92.9 (C-
1), 78.3 (C-3), 76.6 (C-5), 72.4 (C-2), 64.2 (C-6), 62.8 (C-4). 
Quercetin-3-O-rhamn side (4):Yellow amorphous powder, C21 20O11; negative ESI-MS m/z 447 
[M − H]−, 1H-NMR (600 M z, CD3OD): δ 7.33 (1 , d, J = 2.0 Hz, H-2′), 7.31 (1H, dd, J = 2.0, 8.3 Hz, H-
6′), 6.91 (1 , d, J = 8.3 z, H-5′), 6.19 (1H, s, H-6), 6.36 (1H, s, H-8), 5.34 (1 , s, -1′′), 4.22 (1 , brs, H-
2′′), 3 76 (1H, dd, J = 3.2, 9.4 Hz, H-3′′), 3.34 (1H, dd, J = 7.5, 9.4 Hz, H-4′′), 3.41 (1H, m, H-5′′), 0.94 (3H, 
d, J = 6.1 Hz, H-6′′);13C-NMR (150 MHz, CD3OD): δC 18.7 (C-6′′), 7 .1 (C-5′′), 70.6 (C3′′), 71.1 (C-2′′), 
1.2 ( -4′′), 94.3 (C-8), 98.7 (C-6), 02.1 ( - ′ 04 1 10), 115.7 (C-2′), 115.8 (C-5′), 120.8 (C-1′), 122.2 
(C-6′), 134.3 (C-3), 45.4 ( -3′), 148.8 (C-4′), 156.7 (C-2), 1 7.3 (C-9), 161.4 (C-5), 165.6 (C-7), 177.8 (C-
4). 
Myric tin 3-O-rhamnoside (5):Yellow amorphous powder, C21H20O12, negative ESI-MS m/z: 463 
[M − H]−, 1H-NMR (600 MHz, CD3OD): δ 6.95 (2H s, H-2′ 6′), .3  (1 , d, J = 1.6 Hz, H-6), 6.20 (1H, d, 
J = 1.6 z, -8),5. 1 (1H s H-1′′), .80 (1H dd, J = 3.2, 9.5 Hz, H-2′′), 3.55 (1H, m, H-3′′),, 3.17 (1H, m, 
H-4′′), .34 (1H, m, -5′′), 0.84 (3H, d, J = .1Hz, H-6′′). 3C-NMR (150 MHz, CD3OD): δc177.6 (C-4), 
163.8 (C-7), 1 1.4 (C-5), 1 7.1 (C-9), 156.6 (C-2), 145.9 (C-5′, ′), 135.4 ( -4′), 135.2 (C-3), 119.7 (C-1′), 
7.9 (C-2′), 7.9 ( -6′), 104.3 ( -10), 102.4 (C-1′′), 98.8 (C-8), 93.7 (C-6), 71.9 (C-4′′), 71.3 (C-5′′), 70.8 
(C-3′′), 70.3 (C-2′′), 17.8 (C-6′′). 
1,4,6-Tri-O-galloyl-β-D-glucose (6):Off-white amorphous powder, C27H24O18,negative ESI-MS 
m/z 635 [M − H]−; -NMR (600 M z, CD3OD): δH 7.15, 7.10, 7.0  (each 2H, s, galloyl -2′,6′), 5.78 (1H, 
d, J = 8.2 Hz, H-1), 5.22 (1H, t, J = 9.6 Hz, H-4), 4,45 (1H, dd, J = 2.4, 2.0 Hz, H-6a), 4.22 (1 , dd, J = 
12.4, 4.9 Hz, H-6b), 4.06 (1H, ddd, J = 2.0 4 9, 9.6 Hz, H-5), 3.84 (1H, dd, J = 9.2, 9.6 Hz, H-3), 3.65 (1H, 
dd, J = 8.2, 9.2 Hz, H-2). 
3,4,6-Tri-O galloyl-D-gluc se (7):Off-white amorphous powder, C27 24O18, negative ESI-MS m/z 
635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99,6.94 (each 2H, s,galloylH-2′,6′), 4.42 (1H, m, 
H- a), 4.26 (1H, m, -6b), -glucose form: δH 4. 6 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5, 7.8 
Hz, H-2), 5.45 (1/ H, t, J = 9 5 Hz, -3), 5.35 (1/3H dd, J = 9.5 9.8 z, H-4), 4.07 (1/3H, m, H-5), -
glucose form: δ 5.25 (2/3 , d, J = 3.6 Hz, H-1), 3.81 (2/3H, dd, J = 9.8, 3.6 Hz, H-2), 5.68 (2/3H, t, J = 9.8 
Hz, -3), 5.36 (2/3H, t, J = 9.8 Hz,H-4), 4.47 (2/3H, m, H-5). 
2,6-Tri-O-galloyl-β-D-glucose (8): Off-white amorphous powder, C27 24O18, negative ESI-MS: 
m/z 635 [M − H]−, 1 -NMR (600 M z, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′), 5.92 (1H, 
d J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4. 56 (1H, dd, J = 2.0, 12.2 z, H-6a), 4.47 (1H, dd, 
J = 4.8 12.2 Hz, H-6b) 3.83 (1 , ddd, J = 2.0, 4.8 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz, H-3), 3.66 (1H, t, 
J = 9.6 Hz, H-4); 13C-NMR ( 0MHz, D3OD): δ  63.1 (C-6), 69.6 (C-4), 72.7 (C-5), 74.4 (C-3), 74.2 (C-
2) 93.  (C-1), 117.0, 1 9.1, 1 9.2 (galloyl C-1′), 109. , 108.8, 108.8 (galloyl C-2′,6′), 145.3, 145.4, 145.8 
(galloyl C-3′, ′), 138.6, 138.7, 139.1 (galloyl -4′ , 164.1, 164.9, 165.7 (C=O). 
4,6-Di- -galloyl-β-D-gluc se (9):Off-white amorphous powder, C20H20O14, negative ESI-MS: m/z 
483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl H-2′,6′), 5.13 
);
galloyl δC 165.2 (C=O , 146.2 (C-3′,C-5′), 139.7 (C-4′), 119.4 (C-1′), 109.7 (C-2′,C-6′); glucose δC 92.9
(C-1), 78.3 (C-3), 76.6 (C-5), 72.4 (C-2), 64.2 (C-6), 62.8 (C-4).
Quercetin-3-O-rhamnoside (4): Yellow amorphous powder, C21H20O11; negative ESI-MS m/z
447 [M − H]−, 1H-NMR (600 MHz, CD3OD): δ 7 33 (1H, d, J = 2.0 Hz, H-2′), 7.31 (1H, dd, J = 2.0,
8 3 Hz, H-6′), 6.91 (1H d, J = 8.3 Hz, H-5′), 6.19 (1H, s, H-6), .36 (1H, , H-8), 5.34 (1H, s, H-1”),
4.22 ( , brs, H-2”), 3.76 (1 , dd, J = 3.2, 9.4 Hz, -3”), 3.34 (1H, dd, J = 7.5, 9.4 Hz, H-4”), 3.41 ( H,
m, H-5”), 0.94 (3H, d, J = 6.1 Hz, H-6”); 13C-NMR 150 MHz, D3OD): δC 18.7 (C-6” , 71 1 ( -5”),
70.6 (C3”), 71.1 (C-2”), 71.2 (C-4”), 94.3 (C-8), 98.7 (C-6), 102.1 (C-1”), 104.1 (C-10), 115.7 (C-2′), 115.8
(C-5′), 120.8 (C-1′), 122.2 (C-6′), 134.3 (C-3), 145.4 (C-3′), 148.8 ( -4′), 156.7 (C-2), 157.3 (C-9), 161.4 (C-5),
165.6 (C-7), 177.8 (C-4).
Myricetin 3-O-rhamnoside (5): Yellow amorphous powder, C21H20O12, negative ESI MS m/z: 463
[M − H]−, 1H-NMR ( 00 MHz, CD3OD): δ 6.95 (2H, s, H-2′,6′), 6.36 (1H, d, J = 1.6 Hz, H-6), 6.20 ( H,
d, J = 1.6 Hz, H-8), 5.31 (1H, s, H-1”), 3.80 (1H, dd, J = 3.2, 9.5 Hz, H-2”), 3.55 (1H, m, H-3”), 3. 7 (1H,
m, H-4”), 3.34 (1H, m, H-5”), 0.84 (3H, d, J = 6.1 Hz, H-6”). 13C-NMR (150 MHz, CD3OD): δ 177.6
(C-4), 163.8 (C-7), 161.4 (C-5), 157.1 (C-9), 156.6 (C-2), 145.9 (C-5′, 3′), 135.4 (C-4′), 135.2 (C-3), 119.7
(C- ′), 107.9 (C-2′), 107.9 (C-6′), 104. ( -10), 02.4 ( -1”), 8.8 (C-8), 93.7 ( -6), 71.9 ( -4” 1.3 (C-5”),
70.8 -3”), 7 .3 ( 2” 8 6”).
1,4,6-Tri-O-galloyl-β-D-glucose (6): Off-white amorphous powder, C27H24O18, negative ESI-MS
m/z 635 [M − H]−; 1H-NMR (600 MHz, CD3OD): δH 7.15, 7.10, 7.06 (each 2H, s, galloyl H-2′,6′),
5.78 (1H, d, J = 8.2 Hz, H-1), 5.22 (1 , t, J = 9.6 Hz, H-4), 4.45 (1H, dd, J = 12.4, 2.0 Hz, H-6a), 4.22 (1H,
dd, J = 12.4, 4.9 Hz, -6b), 4.06 (1H ddd, J = .0, 4.9, 9.6 z, H-5), 3.84 (1H, dd, J = 9.2, 9.6 Hz, -3),
3 65 (1 , dd, J = 8.2, 9.2 H - ).
3,4,6-Tri-O-galloyl-D-gluc se (7): Off-white amorphous powd r, C27H24O18, ne ti e ESI-MS m/z
635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.07, 6.99, 6.94 (each 2H, s, galloyl H-2′,6′), 4.42 (1H,
m, H-6a), 4.26 (1H, m, H-6b), β-glucose form: δH 4.76 (1/3H, d, J = 7.8 Hz, H-1), 3.56 (1/3H, dd, J = 9.5,
7.8 Hz, H-2), 5.45 (1/3H, t, J = 9.5 Hz, H-3), 5.35 (1/3 , dd, J = 9.5, 9.8 Hz, H-4), 4.07 (1/3H, m, H-5),
α-glucose form: δH 5.25 (2 3H, d, J = 3.6 z, H 1), 3.81 (2/3H, dd, J = 9.8, 3.6 Hz, H-2), 5.68 (2/3H, t,
J = 9.8 Hz, H 3), 5.3 (2/3H, t, J = 9.8 Hz, H-4), 4.47 (2/3 , m, H-5).
1,2,6-Tri-O-galloyl-β-D-glucose (8): Off-white am rphous powder, C27 24O18, negative ESI-MS:
m/z 635 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.10, 7.04, 7.00 (each 2H, s, galloyl H-2′,6′),
5.92 (1H, d, J = 8.5 Hz, H-1), 5.23 (1H, dd, J = 8.5, 9.6 Hz, H-2), 4.56 (1H, dd, J = 2.0, 12.2 Hz, H-6a),
4.47 (1H, dd, J = 4.8, 12.2 Hz, H-6b), 3.83 (1H, ddd, J = 2.0, 4.8, 9.6 Hz, H-5), 3.81 (1H, t, J = 9.6 Hz,
H-3), .66 ( H, t, J = 9. Hz, H-4); 13C-NMR (150 MHz, CD OD): δC 63.1 (C- ), 69.6 (C-4), 72.7 (C-5),
Molecules 2019, 24, 145 4 of 11
74.4 (C-3), 74.2 (C-2), 93.2 (C-1), 117.0, 119.1, 119.2 (galloyl C-1′), 109.2, 108.8, 108.8 (galloyl C-2′,6′),
145.3, 145.4, 145.8 (galloyl C-3′,5′), 138.6, 138.7, 139.1 (galloyl C-4′), 164.1, 164.9, 165.7 (C=O).
4,6-Di-O-galloyl-β-D-glucose (9): Off-white amorphous powder, C20H20O14, negative ESI-MS:
m/z 483 [M − H]−, 1H-NMR (600 MHz, CD3OD): δH 7.09, 7.07, 7.08, 7.06 (each 1H, s, 2× galloyl
H-2′,6′), 5.13 (1H, t, J = 9.4 Hz, H-4), 4.39 (1H, m, H-6a), 4.18 (1H, m, H-6b), α-glucose form: 5.17 (1/2H,
d, J = 3.7 Hz, H-1), 3.98 (1/2H, t, J = 9.4 Hz, H-3), 4.53 (1/2H, dd, J = 3.7, 9.6 Hz, H-2), β-glucose form:
δH 4.60 (1/2H, d, J = 7.8 Hz, H-1), 3.89 (1/2H, m, H-5), 3.70 (1H, t, J = 9.3 Hz, H-3), 3.31 (1/2H, dd,
J = 9.3, 7.8 Hz, H-2).
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Figure 1. Structures of co pou s (1–9) is late fr icinodendron heudelotii.
2.3. Bioassay
In an in vitro cytotoxicity assay, compounds 1–5 were applied to HL-60, SMMC-7721, A-549,
MCF-7, and SW-480 cancer cells to assess their cytotoxic effects. Compound 3 (Corilagin) exhibited
the most cytotoxic activity against MCF-7 cells with IC5 values of 33.18 and 25.81 µg/mL for HL-60
cells. The IC50 value of co pound 3 in F-7 cells is co parable with the positive control drug
(cisplatin), having an I 5 alue of 27.43 (Table 1). Corilagin had 29.19, 4.91, and 49.82% inhibition
for A-549, S MC-7721, and SW-480 respectively. The inhibition rate of other compounds (gallic acid,
gallic acid ethyl ester, quercetin-3-O-rhamnoside, myricetin-3 O-rhamnoside) wasless than 50% at the
concentration of 40 µM (Table 2), sugge tin that they showed no sig ifica t inhibitory activity against
the ca cer c ll lin s; therefore, their IC50 values were not m asured.
Figures 2–4 shows the photomicrograph of the cytotoxic a tivities of c mpound 3 on breast, colon,
and leukemia cancer cell li es with relatively similar activity when compared with cisplatin (control group).
Table 1. IC50 values (µg/mL) of corilagin (3) isolated from R. heudelotii against some cancer cell lines.
Sample HL-60 MCF-7 SW480 BEAS-2B
Corilagin (3) 25.81 ± 0.67 * 33.18 ± 0.76 * 37.04 ± 1.06 * 16.32 ± 1.43
Cisplatin 2.32 ± 0.07 27.43 ± 1.26 10.19 ± 1.03 —
* Significant (p < 0.05) when compared to the control (Cisplatin).
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Table 2. Percentage of inhibition (I%) of compounds 1–5 (40 µM) isolated from R. heudelotii on different
cell lines.
Compounds HL-60 A-549 SMMC-7721 MCF-7 SW480
1 14.80 ± 5.00 13.67 ± 2.91 5.85 ± 1.16 18.41 ± 4.00 10.04 ± 3.51
2 12.26 ± 2.29 11.82 ± 0.14 5.19 ± 0.83 24.76 ± 3.30 1.15 ± 0.28
3 76.23 ± 0.51 29.19 ± 1.42 4.91 ± 1.43 57.93 ± 3.19 49.82 ± 3.80
4 4.56 ± 2.61 5.49 ± 2.01 1.12 ± 1.05 14.95 ± 0.82 2.44 ± 2.49
5 0.65 ± 2.87 8.32 ± 3.46 1.62 ± 1.05 10.67 ± 4.05 12.45 ± 3.66
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3. Discussion
After many years of research on cancer, cancer still remains a destructive disease responsible for
over one quarter of the deaths recorded globally. It is one of the major health obstacles, representing
the second largest cause of mortality [24]. This is mainly because cancer chemotherapy is often
mitigated by a high degree of toxicity to normal cells or failure of treatment due to the development
of resistance to anticancer drugs. However, medicinal plants have been increasingly shown to
possess anticancer properties, and this has recently become the subject of some scientific studies [25]
because they are considered to be less toxic and can be effective for treatment of different diseases.
To date, the therapeutic pre-clinical screening of medicinal plants against multiple cancer cells and
characterization of the bioactive components in these plants are limited. Our study reports a bioactive
compound with cytotoxicity effects in the leaf extracts of R. heudelotii and its potential to be developed
for use for cancer treatment.
Corilagin (compound 3) was isolated and structurally identified from the ethyl acetate fraction
of the ethanolic extract of R. heudelotii leaves in our study. Only compound 3 showed significant
and comparable cytotoxic property relative to cisplatin. Corilagin has been previously identified
in several other plants, especially those of the Euphorbiaceae family. It was firstly isolated from
Caesalpinia coriaria in 1951, hence the name of the molecule [26]. It was later identified as a weak carbonic
anhydrase inhibitor [27]. Studies have reported its antibacterial, hepatoprotective, anti-oxidant [28],
anti-inflammatory [29], anti-hypertensive [30], and anti-tumor activities [31]. Yang et al. [32] reported
that corilagin can block glioblastoma cells and stem-like cells’ proliferation. In this study, corilagin
was found to exhibit an inhibitory effect on HL-60, MCF-7, and SW480 cell growth by 76.23, 57.93,
and 49.82%, respectively (Table 2). This could be linked to its ability to activate the Jun N-terminal
kinase (JNK) signaling pathway [33]. When these pathways are turned on, it can lead to the activation
of the proapoptotic β-cell lymphoma 2 (Bcl-2) protein through phosphorylation and/or upregulation
of gene expression and hence mitochondrial cell death [34]. Breast cancer cells treated with corilagin
showed reduced cell diameters when compared to the untreated cells, implying that the compound
caused cell death of most of the cancerous cells (Plate 1). Corilagin is an ellagitannin, which have
been reported to induce pro-apoptotic effects in in both MDA-MB-231 and MCF-7 breast cancer
cells [35]. Kuo et al. [36] observed that ellagitannins from Terminalia arjuna bark extract induced
apoptosis in A549 cells and in human breast adenocarcinoma MCF-7 cells via blockage of cell-cycle
progression in the G0/G1 phase. The cytotoxic properties of tannins are characterised by the release
of reactive oxygen species (ROS), which is followed by a reduction in the thioredoxin, superoxide
dismutase, and in the level of redox active proteins [37]; this might explain the cytotoxic activity of
compound 3. The chemopreventive activity of tannins, especially the ellagitannins and hydrolysable
tannins, has been linked to activation of apoptosis [38]. According to the findings of Jia et al. [31],
corilagin inhibited SKOv3ip by inducing cell cycle arrest and enhancing apoptosis in the cancer cell
lines. Down regulation of cyclin B1 and phosphor-cdc 2 after corilagin treatment on cancer cells
was discovered [31]. Corilagin has also been reported to cause the release of TNF-α inhibitor in
inflammation [39], decrease the secretion of the transforming growth factor beta 1 (TGF-β1) in a dose
dependent manner [31], and inhibit hepatitis C viral replication in vitro [40]. Corilagin enhanced
apoptosis by inducing cell cycle arrest at the G2/M stage in ovarian cancer cells. Anti-cancer strategies
have focused on possible ways of deactivating the G2/M checkpoint, thereby causing cancer cells to
undergo mitosis, and leading to increased DNA damage and then cell death [41,42]. Ming et al. [43]
also reported the inhibitory action of corilagin on hepatocellular carcinoma cells (HCC) at the G2/M
phase by upregulating p53 and p21, and downregulating cyclin B1, cdc 2, and pAKT. Selectivity index
(SI) signifies the differential activity of compounds; the greater the SI value, the more selective the
compound [44]. The SI data, as shown in Table 3, indicate that corilagin was non-selective to HL-60,
MCF-7, and SW480 cancer cell lines. This suggests its general toxicity to the cell. Adverse effects
caused by treatment and increased resistance to tumor cells, leading to treatment failure, has led to a
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search for therapeutic alternatives. Therefore, it is important to find selective bioactive compounds
that could arrest tumor cell proliferation.
Table 3. Selectivity index of compound 3 (corilagin).
Sample HL-60 MCF-7 SW480
Corilagin (3) 0.63 0.49 0.44
4. Materials and Methods
4.1. General Experimental Procedures
1D- and 2D-NMR spectra were recorded in CD3OD and acetone-d6 with Bruker Avance III600
spectrometer (Bruker, Fällande, Switzerland) operating at 600 MHz for 1H-NMR, and 150 MHz for
13C-NMR, respectively. Coupling constants are expressed in hertz (Hz), and chemical shifts are given
on a δ (parts per million, ppm) scale with tetramethylsilane (TMS) as an internal standard. ESI mass
spectra were recorded on a VG Auto Spec-300 spectrometer (Waters, Milford, MA, USA). Column
chromatography (CC) was performed on Sephadex LH-20 (25–100 µm, GE Healthcare Bio-Science
AB, Uppsala, Sweden), MCI-gel CHP20P (75–150 µm, Mitsubishi Chemical Co, Ltd., Tokyo, Japan),
and Toyopearl HW-40F (Tosoh Co. Ltd., Tokyo, Japan). Thin-layer chromatography (TLC) was
performed on silica gel H-precoated plates, 0.2–0.25 mm thick (Qingdao Haiyang Chemical Co.,
Qingdao, China), with benzene–ethylformate–formic acid (3:6:1 or 2:7:1, v/v), and compounds were
detected by spraying with 2% ethanolic FeCl3 and 10% sulfuric ethanol solution followed by heating.
4.2. Plant Sample Collection
Ricinodendron heudelotii leaves were collected within Covenant University premises Ota, Ogun,
Nigeria. The plant was identified by Dr. J.O. Popoola (Botanist, Biological Science Department,
Covenant University, Ota, Ogun State, Nigeria) and a voucher specimen was prepared and submitted
in the Forest research Institute of Nigeria, Ibadan with voucher number, FHI 110573. Leaves were
dried at room temperature (25 ◦C) and blended using an electric blender into a coarse powder.
4.3. Extraction and Solvent Partitioning ofthe Crude Extract
The powdered leaf samples (10 kg) were extracted using 95% ethanol by macerationat room
temperature, the filtrate was further condensed under reduced temperature and pressure, and the
yield of the extract obtained was 11.75%. The concentrated crude extract (1 kg) was suspended in 1 L
distilled water and partitioned in sequence with petroleum ether (Pet; 8 L), ethyl acetate (EtOAc; 8 L),
and n-butanol (8 L). The solvent fractions were concentrated to dryness to afford four (4) fractions
as: Pet, EtOAc, n-butanol, and aqueous fractions. The EtOAc fraction was selected for subsequent
isolation procedures.
4.4. Isolation of Compounds fromthe Partitioned Fraction
The ethylacetate fraction (246 g) was loaded into a column containing Sephadex LH-20 (800 g).
The eluent was a mixture of water and methanol in different ratios starting with 100:0 to 0:100.
Fractions with similar TLC patterns were combined to afford 13 fractions. Fraction 11 (36 g) was
chromatographed on a Sephadex LH-20 column and MCI-gel CHP20P eluting with water:methanol
(4:1) to afford compounds 1 (8.53 mg), 2 (2.1 mg), and 3 (12 mg). Fraction 12 (3.8 g) was subjected to
repeated column chromatography also eluting with H2O and methanol (60:1) to afford compound 4
(98 mg) and 5 (13.2 mg). Compounds 6 (9.9 mg), 7 (2.6 mg), 8 (2.7 mg), and 9 (4.4 mg) were obtained
from fraction 13 (14.5 g) after repeated purification by chromatography on a Sephadex LH-20, MCI-gel
CHP20P and Toyopearl HW-40F columns eluting with H2O/methanol.
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4.5. Bioassay
4.5.1. Cell Culture
Cancer cell lines, HL-60, SMMC-7721, A-549, MCF-7, and SW-480, were obtained from the
American Type Culture Collection Center (ATCC) (Manassas, VA, USA). They were cultured in
RMPI-1640 or DMEM medium supplemented with 10% bovine serum albumin (Gibco, Grand Island,
NY, USA). Prior to exposure to drugs, the cancer cell lines were cultured in a CO2 incubator for 48 h
and the cell density was adjusted to 5 × 104 cells/well.
4.5.2. Sample Preparation
Compounds (1 mg/mL) were dissolved in either DMSO or H2O depending on their solubility.
Samples (2 µL) were suspended in centrifuge tubes containing 48 µL of complete medium to make a
final volume of 100 µL.
4.5.3. Assay Procedures
The cytotoxicity assay was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) method by measuring the
absorbance of formazan precipitate formed in the cells based on MTS reduction [45]. In this assay,
cells were seeded into each of the wells of 96-well cell culture plates, incubated for 12h at 37 ◦C,
and then the test compounds (40 µM) were added and allowed to incubate for 48 h. Each cell line
was exposed to different concentrations (0.064, 0.32, 1.6, 8, and 40 µM) of the test compounds in
triplicates using cisplatin-an anticancer drug as the positive control. The absorbance of the lysate was
measured using a 96-well micro plate reader (Bio-Rad 680, Hercules, CA, USA) at 490 nm. Compounds
with a growth inhibition rate of 50% were further evaluated at concentrations of 0.064, 0.32, 1.6, 8,
and 40 µM in triplicates with cisplatin as positive control. The concentration that inhibited 50% of the
cell growth were expressed as IC50, which was calculated using Reed and Muench’s method [46,47].
The percentage inhibition (I%) was calculated as follows:
Inhibition (%) = (Cc − Cs)/Cc × 100 (1)
where Cc = viable cell count of negative control, Cs = viable cell count of sample, IC50 was calculated
by the following equation:
Log10 (IC50) = (Log10 (CL) (IH − 50) + log10 (CH) (50 − IL))/(IH − IL) (2)
IC50 = 10 Log10 (IC50); IH: I% above 50%; IL: I% below 50%; CH: High drug concentration; and CL: Low
drug concentration.
4.6. Selectivity Index
The selectivity index (SI) for the cytotoxicity of corilagin was calculated using the ratio of the IC50
value of the compound on a normal cell line to the IC50 value of the compound on cancer cell lines [48].
4.7. Statistical Analysis
Samples are expressed as mean ± standard deviation or standard error of mean.
5. Conclusions
In conclusion, we report significant cytotoxic activities of corilagin isolated from leaf extract of
R. heudelotii on a breast cancer cell line, and its potential for development as an anticancer agent to
reduce the burden of cancer diseases globally.
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